PET/CT
Devicepositron emission tomography/computed tomography
NCT Number: NCT07127627
The aim of the study is to identify and characterize lesions in the abdominopelvic region detected by 18fluorine- fluorodeoxyglucose (FDG) positron Emission Tomography combined Computed Tomography (PET/CT) scan, including determining their malignant or benign nature, and to determine the extent of disease to facilitate proper management
Trial opening soon.
Get NotifiedAll sexes
Observational
positron Emission Tomography combined Computed Tomography is a hybrid imaging that provides both anatomical and functional data that helps to differentiate between benign and malignant diseases. [18F]FDG is taken up by both normal cells utilizing glucose like (kidneys, ureters and urinary bladder due to urinary excretion, Variable degrees of uptake can also seen in the liver, spleen, bone marrow, bowel, testes and uterus) .and also the tumor cells which usually have a high glucose demand. This uptake is mediated by the cell surface carrier molecules designated as glucose transporters (GLUT) and can be measured with the semi quantitative index called standardized uptake values (SUV) Cancer cells divide rapidly and have greater metabolic rates. Through the upregulation of glucose transport proteins on the cell membrane, cancer cells exhibit enhanced glucose uptake . Studies have demonstrated that SUV of 2.5 can differentiate malignant versus benign tissues , thus, Proper characterization of abdomino-pelvic lesions will lead to improve chances for successful management and treatment.
Multiple studies have shown that Dual-time point (DTP) 18F-FDG PET/CT may provide more help in the differentiation of malignant lesions from benign ones.as Dual-Time-Point PET/CT involves two scans, one early and one delayed, allowing for the assessment of FDG uptake kinetics, malignant tumors tend to show increased FDG uptake over time, indicating higher glucose metabolism. But benign Lesions or those with inflammatory processes may show a decrease or no significant change in FDG uptake over time.
FDG activity in urine interferes with tumor activity. Therefore, the value of FDG PET has only a limited role in detecting tumors in the bladder wall and urinary tract, Thus several methods have been investigated and tested to reduce urine FDG activity: catheterization, dual-phase imaging, early PET images, late PET images after voiding, oral hydration, and forced diuresis
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
positron emission tomography/computed tomography
Time frame: 3 years
identify and characterize abdominopelvic lesions, initial staging, follow up of treatment and detection of recurrence in the abdominopelvic region, including determining their malignant or benign nature, and to determine the extent of disease, Assess the spread of disease to lymph nodes, distant metastases, or other areas, to facilitate proper management.
Time frame: 3 years
Evaluate the diagnostic power of alternative technologies like dual time point images, bladder evacuation and forced diuresis in characterizing abdominopelvic lesions.
Contact information is provided by the study sponsor or research team.
salma A samy, ass. lecturer
CONTACT
waleed A diab, ass. prof
CONTACT
Assiut University
Other
Characterization of Abdomino-pelvic Lesions in Cancer Patients by 18F-FDG PET/CT
Acronym: 18F-FDG PET/CT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06504316
AKI - Acute Kidney Injury, Abdominal Sepsis
Shanghai, China
View Trial DetailsNCT04325685
Abdominal Sepsis, Accidental Injuries
Severodvinsk, Arkhangelskaya oblast, Russia
View Trial DetailsNCT04323150
Abdominal Sepsis, Accidental Injuries
Severodvinsk, Russia
View Trial DetailsNCT01410526
Abdominal Sepsis, Digestive System Diseases
Thessaloniki, Greece
View Trial Details